# US 10,766,943 B2 · Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,766,943 B2
- Document ID: US10766943B2
- Status: Granted
- Kind: B2
- Application number: 16/513,672
- Filed: 2019-07-16
- Published: 2019-11-21
- Granted: 2020-09-08
- Earliest claimed: 2014-08-29
- Assignees: GEMoaB Monoclonals GmbH
- Applicants: GEMoaB Monoclonals GmbH
- Inventors: Michael Bachmann; Armin Ehninger
- Web page: https://patentgrep.com/patent/US10766943B2

## CPC

- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/42: Cancer antigens
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to immune cell-based anti-cancer therapeutics and methods of using the therapeutics in the treatment of cancer.

## Claims

### Claim 1

An antibody or fragment thereof that specifically binds CD33, wherein said antibody or antibody fragment comprises a single chain variable fragment (scFV) that comprises a humanized light chain variable domain comprising the amino acid sequence of SEQ ID NO:40 and a humanized heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:41, wherein said light chain variable domain and said heavy chain variable domain are connected by a linker peptide that is about 10 to 25 amino acids in length.

### Claim 2 (depends on 1)

The antibody or antibody fragment of claim 1 wherein the N-terminus of the amino acid sequence of SEQ ID NO:40 is connected to the C-terminus of the amino acid sequence of SEQ ID NO:41.

### Claim 3 (depends on 1)

The antibody or antibody fragment of claim 1 wherein said linker peptide comprises the amino acid sequence of amino acids 413-427 of SEQ ID NO. 32.

### Claim 4 (depends on 1)

The antibody or antibody fragment of claim 1 further comprising a second scFV against a second antigen.

### Claim 5 (depends on 1)

A nucleic acid encoding the antibody or antibody fragment of claim 1.

### Claim 6 (depends on 5)

The nucleic acid of claim 5, comprising the nucleotide sequence of SEQ ID NO. 21 and the nucleotide sequence of SEQ ID NO. 22.

### Claim 7 (depends on 1)

A pharmaceutical composition comprising the antibody or antibody fragment of claim 1 and a pharmaceutically acceptable excipient.

### Claim 8 (depends on 4)

A pharmaceutical composition comprising the antibody or antibody fragment of claim 4 and a pharmaceutically acceptable excipient.

### Claim 9 (depends on 1)

The antibody or antibody fragment of claim 1 wherein said linker peptide comprises the amino acid sequence of amino acids 135-159 of SEQ ID NO. 30.